ECSP20081591A - Proteínas de fusión que comprenden progranulina - Google Patents
Proteínas de fusión que comprenden progranulinaInfo
- Publication number
- ECSP20081591A ECSP20081591A ECSENADI202081591A ECDI202081591A ECSP20081591A EC SP20081591 A ECSP20081591 A EC SP20081591A EC SENADI202081591 A ECSENADI202081591 A EC SENADI202081591A EC DI202081591 A ECDI202081591 A EC DI202081591A EC SP20081591 A ECSP20081591 A EC SP20081591A
- Authority
- EC
- Ecuador
- Prior art keywords
- progranulin
- fusion proteins
- proteins including
- proteins
- ftd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan en la presente proteínas de fusión que comprenden progranulina y un polipéptido Fc. También se proporcionan en la presente métodos para el uso de dichas proteínas para el tratamiento de trastornos asociados con la progranulina (por ejemplo, una enfermedad neurodegenerativa, tal como demencia frontotemporal (FTD)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862686579P | 2018-06-18 | 2018-06-18 | |
US201862746338P | 2018-10-16 | 2018-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20081591A true ECSP20081591A (es) | 2021-01-29 |
Family
ID=67138158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202081591A ECSP20081591A (es) | 2018-06-18 | 2020-12-16 | Proteínas de fusión que comprenden progranulina |
Country Status (17)
Country | Link |
---|---|
US (2) | US20210284702A1 (es) |
EP (1) | EP3807322A1 (es) |
JP (1) | JP2021527656A (es) |
KR (1) | KR20210027377A (es) |
CN (1) | CN112424233A (es) |
AU (1) | AU2019288212A1 (es) |
BR (1) | BR112020025306A2 (es) |
CA (1) | CA3101202A1 (es) |
CL (1) | CL2020003255A1 (es) |
EC (1) | ECSP20081591A (es) |
IL (1) | IL279510A (es) |
MX (1) | MX2020012518A (es) |
PE (1) | PE20210323A1 (es) |
PH (1) | PH12020552189A1 (es) |
SG (1) | SG11202011743SA (es) |
TW (1) | TW202016152A (es) |
WO (1) | WO2019246071A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2899227T3 (es) | 2015-04-07 | 2022-03-10 | Alector Llc | Anticuerpos anti sortilina y métodos de uso de los mismos |
RU2020115485A (ru) * | 2015-05-29 | 2020-06-11 | Регенерон Фармасьютикалс, Инк. | Животные, отличные от человека, с нарушением в локусе c9orf72 |
AU2018221731C1 (en) | 2017-02-17 | 2021-11-18 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
KR20230065382A (ko) | 2018-07-13 | 2023-05-11 | 알렉터 엘엘씨 | 항-소틸린 항체 및 이들의 사용 방법 |
WO2020037150A2 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
KR20220130678A (ko) | 2019-12-23 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 프로그라눌린 변이체들 |
BR112022013756A2 (pt) | 2020-01-13 | 2022-10-11 | Denali Therapeutics Inc | Anticorpos anti-trem2 e métodos de uso dos mesmos |
US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
JP2023542178A (ja) * | 2020-09-18 | 2023-10-05 | アイユーシーエフ-エイチワイユー(インダストリー-ユニバーシティ コーオペレーション ファウンデーション ハンヤン ユニバーシティ) | PTPsigma-Fc融合タンパク質およびそれを含む薬学組成物 |
PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
WO2022082178A2 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
AR128003A1 (es) * | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
WO2023198661A1 (en) * | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
WO2023224956A1 (en) * | 2022-05-16 | 2023-11-23 | Denali Therapeutics Inc. | Transferrin receptor-binding domains and proteins comprising the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
ES2899227T3 (es) * | 2015-04-07 | 2022-03-10 | Alector Llc | Anticuerpos anti sortilina y métodos de uso de los mismos |
HRP20220304T1 (hr) * | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferinska receptorska protutijela s prilagođenim afinitetom |
CN107698684B (zh) * | 2016-08-03 | 2021-09-28 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白 |
SG11201907419PA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Transferrin receptor transgenic models |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 AU AU2019288212A patent/AU2019288212A1/en active Pending
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko active Search and Examination
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en unknown
- 2019-06-18 TW TW108121124A patent/TW202016152A/zh unknown
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 JP JP2020570444A patent/JP2021527656A/ja active Pending
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 IL IL279510A patent/IL279510A/en unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021527656A (ja) | 2021-10-14 |
CA3101202A1 (en) | 2019-12-26 |
PE20210323A1 (es) | 2021-02-18 |
BR112020025306A2 (pt) | 2021-03-09 |
CL2020003255A1 (es) | 2021-05-28 |
KR20210027377A (ko) | 2021-03-10 |
US20210284702A1 (en) | 2021-09-16 |
EP3807322A1 (en) | 2021-04-21 |
IL279510A (en) | 2021-01-31 |
CN112424233A (zh) | 2021-02-26 |
US20230406898A1 (en) | 2023-12-21 |
AU2019288212A1 (en) | 2020-12-03 |
SG11202011743SA (en) | 2021-01-28 |
WO2019246071A1 (en) | 2019-12-26 |
PH12020552189A1 (en) | 2021-06-28 |
TW202016152A (zh) | 2020-05-01 |
MX2020012518A (es) | 2021-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
PE20230036A1 (es) | Variantes de progranulina | |
CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
CL2020000810A1 (es) | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas. | |
SV2018005612A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
CR20190480A (es) | Uso de antagonistas de klk5 para el tratamiento de una enfermedad | |
CL2022001712A1 (es) | Variantes de progranulina | |
CL2019002155A1 (es) | Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. | |
AR115565A1 (es) | Proteínas de fusión que comprenden progranulina | |
ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
BR112018071123A2 (pt) | (+)-azasetron para uso no tratamento de distúrbios de ouvido | |
MX2022014899A (es) | Variantes y composiciones del lfa3 y sus usos. | |
EA202190062A1 (ru) | Слитые белки, содержащие програнулин | |
AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
TH72941B (th) | อุปกรณ์สำหรับการนำส่งสิ่งปลูกฝังเทียมและวิธีการใช้พวกมัน | |
UA97336U (en) | Glasses-transformers |